Probing the interaction of Rivastigmine Tartrate, an important Alzheimer's drug, with serum albumin: Attempting treatment of Alzheimer's disease.
Alzheimer's disease
CD spectroscopy
Fluorescence spectroscopy
Molecular docking
Molecular dynamics simulation
Serum albumin
Journal
International journal of biological macromolecules
ISSN: 1879-0003
Titre abrégé: Int J Biol Macromol
Pays: Netherlands
ID NLM: 7909578
Informations de publication
Date de publication:
01 Apr 2020
01 Apr 2020
Historique:
received:
27
10
2019
revised:
11
01
2020
accepted:
14
01
2020
pubmed:
20
1
2020
medline:
2
12
2020
entrez:
20
1
2020
Statut:
ppublish
Résumé
The present study was aimed at investigating the binding between an important drug of Alzheimer's therapy, Rivastigmine tartrate (RT), with Bovine serum albumin (BSA). BSA is a model protein that is increasingly being used for studies related to drug-protein interaction owing to its structural similarity with human serum albumin (HSA) which is extremely abundant in the circulatory system comprising around 60% of the total plasma protein. Fluorescence spectroscopy implied that complex formation is taking place between BSA and RT; binding constant calculated was of the order of 10
Identifiants
pubmed: 31954794
pii: S0141-8130(19)38743-4
doi: 10.1016/j.ijbiomac.2020.01.134
pii:
doi:
Substances chimiques
Serum Albumin
0
Rivastigmine
PKI06M3IW0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
533-542Informations de copyright
Copyright © 2020. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no competing financial interests.